SCHEMBL902310

SCHEMBL902310

NCCCC(N)c1ccnc2cc(Cl)ccc12

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FERMT2 Q96AC1 4/20 0.56
NR4A2 P43354 3/20 0.50
SOS2 Q07890 1/20 0.50
CYP1A2 P05177 1/20 0.49
CCR1 P32246 1/20 0.47
CHRM1 P11229 2/20 0.41
KCNH2 Q12809 2/20 0.41
PDE3A Q14432 2/20 0.41
CYP3A4 P08684 1/20 0.41
DRD3 P35462 1/20 0.41
OPRK1 P41145 1/20 0.41
PDE4D Q08499 1/20 0.41
HRH3 Q9Y5N1 1/20 0.41
TDP1 Q9NUW8 2/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C19 P33261 1/20 0.41
PRNP P04156 1/20 0.41
APP P05067 1/20 0.41
CHRM2 P08172 1/20 0.41
CHRM4 P08173 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4367045 0.96 FERMT2 (0.56) FERMT2NR4A2SOS2CYP1A2CCR1
SCHEMBL4365534 0.93 FERMT2 (0.55) FERMT2NR4A2SOS2CYP1A2CCR1
SCHEMBL5275609 0.85 NR4A2 (0.56) FERMT2NR4A2SOS2CYP1A2CCR1
SCHEMBL4374933 0.84 NR4A2 (0.46) FERMT2NR4A2SOS2CYP1A2CCR1
SCHEMBL6661654 0.83 NR4A2 (0.50) FERMT2NR4A2SOS2CYP1A2CCR1
SCHEMBL29625389 0.83 NR4A2 (0.50) FERMT2NR4A2SOS2CYP1A2CCR1
SCHEMBL4374938 0.81 CCR1 (0.49) FERMT2NR4A2SOS2CYP1A2CCR1
SCHEMBL6661655 0.81 FERMT2 (0.53) FERMT2NR4A2SOS2CYP1A2CCR1
SCHEMBL15924403 0.79 LOXL2 (0.50) FERMT2CYP1A2CYP3A4TDP1CYP2D6
SCHEMBL4374931 0.77 FERMT2 (0.52) FERMT2NR4A2SOS2CYP1A2CCR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120264810-A1 COMPOSITIONS AND METHODS FOR ENHANCING CELLULAR UPTAKE AND INTRACELLULAR DELIVERY OF LIPID PARTICLES THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2012-10-18 US disclosed
WO-2012041493-A1 AMINOQUINOLINIUM SALTS, METHODS OF THEIR PRODUCTION AND THEIR USE AS ACTIVE AGENTS FOR BIOTECHNOLOGICAL AND MEDICAL APPLICATIONS AGAINST BINARY TOXINS JULIUS-MAXIMILIANS-UNIVERSITÄT WÜRZBURG (DE) 2012-04-05 WO disclosed
WO-2011036557-A1 COMPOSITIONS AND METHODS FOR ENHANCING CELLULAR UPTAKE AND INTRACELLULAR DELIVERY OF LIPID PARTICLES THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2011-03-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120264810-A1 COMPOSITIONS AND METHODS FOR ENHANCING CELLULAR UPTAKE AND INTRACELLULAR DELIVERY OF LIPID PARTICLES NPC1L1, ABCB4, NPC1 FERMT2 1125/4885NR4A2 2060/4885SOS2 4063/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.